Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiology
Study identifies role for Axl in angiogenesis and tumor growth
November 18th, 2005
Rigel Pharmaceuticals, Inc. (RIGL) announced that Cancer Research, the journal of the American Association for Cancer Research (AACR), published findings from studies done at Rigel that identified and characterized a role for the receptor tyrosine kinase Axl in angiogenesis and tumor growth. Scientists at Rigel found that Axl signaling controls diverse processes in endothelial cells, including growth, survival, migration, and morphologic differentiation - mechanisms that are central to tumor growth and formation. As part of an effort to develop novel therapeutic strategies for cancer treatment, Rigel researchers developed a unique genetic...
Source: Drug Week (2005-11-18)
|
